Skip to main content

Table 2 The average dosimetric characteristic for the fourteen patients

From: Improve the dosimetric outcome in bilateral head and neck cancer (HNC) treatment using spot-scanning proton arc (SPArc) therapy: a feasibility study

StructureValueSPArcIMPTpValue
CTV_highD95(Gy) [RBE]70.8 ± 0.270.7 ± 0.20.975
 D5(Gy) [RBE]73.6 ± 0.874.1 ± 0.70.011
 HI1.04 ± 0.011.05 ± 0.010.005
 CI0.70 ± 0.060.67 ± 0.070.006
CTV_lowD95(Gy) [RBE]60.8 ± 0.460.8 ± 0.40.777
 D5(Gy) [RBE]64.6 ± 1.065.7 ± 1.70.003
 HI1.07 ± 0.041.09 ± 0.050.003
 CI0.54 ± 0.090.51 ± 0.100.017
CordD1(Gy) [RBE]17.2 ± 7.021.7 ± 7.90.009
Brain StemD1(Gy) [RBE]14.2 ± 11.115.9 ± 11.30.048
Contralateral ParotidMean Dose (Gy) [RBE]17.9 ± 6.422.6 ± 5.30.001
Ipsilateral ParotidMean Dose (Gy) [RBE]21.1 ± 7.428.4 ± 6.20.001
Oral CavityMean Dose (Gy) [RBE]21.9 ± 9.727.5 ± 9.40.001
ExternalID (Gy · L)121.8 ± 29.7147.0 ± 33.80.001
V1Gycc6186.9 ± 1800.15852.7 ± 1543.50.011
V3Gycc4710.8 ± 1328.45137.8 ± 1331.70.008
  1. Abbreviations: HI (homogeneity index), RBE relative biological effectiveness, Dx the maximum dose covering x% volume of a structure, ID the integral dose, Vx the volume of a structure received x Gy [RBE]